The present disclosure provides a polyherbal composition for preventing and alleviating Polycystic ovary syndrome. The composition comprises an insulin regulator selected from Cinnamomum zeylyanicum and Trigonella foenum, a blood sugar regulator selected from Garcinea cambogia and Emblica officinalis, a cholesterol lowering agent selected from Linum usittatissimum and Tribulus terrestris, a prolactin regulator selected from Vitex agnus-castus and Trachyspermum ammi, a cyst shrinking component selected from Zingiber officinale and Putranjiva roxburghii, an androgen regulator selected from Ocimum sanctum, Glycyrrhiza glabra and Mentha spicate, an adrenal gland regulator selected from Withania somnifera and Sesamum indicum, an inositol containing component selected from Oryza sativa and Cicer arietinum, a binder selected from Ferula foetida and Prunus amygdalus along with a pharmaceutically acceptable excipient.

The present disclosure provides a polyherbal composition for preventing and alleviating Polycystic ovary syndrome. The composition comprises an insulin regulator selected from Cinnamomum zeylyanicum and Trigonella foenum, a blood sugar regulator selected from Garcinea cambogia and Emblica officinalis, a cholesterol lowering agent selected from Linum usittatissimum and Tribulus terrestris, a prolactin regulator selected from Vitex agnus-castus and Trachyspermum ammi, a cyst shrinking component selected from Zingiber officinale and Putranjiva roxburghii, an androgen regulator selected from Ocimum sanctum, Glycyrrhiza glabra and Mentha spicate, an adrenal gland regulator selected from Withania somnifera and Sesamum indicum, an inositol containing component selected from Oryza sativa and Cicer arietinum, a binder selected from Ferula foetida and Prunus amygdalus along with a pharmaceutically acceptable excipient.

The present disclosure provides a polyherbal composition for preventing and alleviating Polycystic ovary syndrome. The composition comprises an insulin regulator selected from Cinnamomum zeylyanicum and Trigonella foenum, a blood sugar regulator selected from Garcinea cambogia and Emblica officinalis, a cholesterol lowering agent selected from Linum usittatissimum and Tribulus terrestris, a prolactin regulator selected from Vitex agnus-castus and Trachyspermum ammi, a cyst shrinking component selected from Zingiber officinale and Putranjiva roxburghii, an androgen regulator selected from Ocimum sanctum, Glycyrrhiza glabra and Mentha spicate, an adrenal gland regulator selected from Withania somnifera and Sesamum indicum, an inositol containing component selected from Oryza sativa and Cicer arietinum, a binder selected from Ferula foetida and Prunus amygdalus along with a pharmaceutically acceptable excipient.

The present invention is directed to a dietary supplement comprising a trans form of Menaquinone-7 (MK-7). In some embodiments, the dietary supplement may further comprise at least one chondroprotective agent. In some embodiments, the dietary supplement comprises metal ions selected from the group consisting of zinc ions, copper ions, manganese ions, magnesium ions, iron ions, chromium ions, calcium ions, and combinations thereof.

The present invention is directed to a dietary supplement comprising a trans form of Menaquinone-7 (MK-7). In some embodiments, the dietary supplement may further comprise at least one chondroprotective agent. In some embodiments, the dietary supplement comprises metal ions selected from the group consisting of zinc ions, copper ions, manganese ions, magnesium ions, iron ions, chromium ions, calcium ions, and combinations thereof.

The present invention is directed to a dietary supplement comprising about 120 mcg of a trans form of Menaquinone-7 (MK-7). In some embodiments, the dietary supplement may further comprise a combination of green-lipped mussel powder and eggshell membrane powder. In other embodiments, the dietary supplement may comprise vitamin D3, vitamin C, and Ginger roots extract.

The present invention is directed to a dietary supplement comprising about 120 mcg of a trans form of Menaquinone-7 (MK-7). In some embodiments, the dietary supplement may further comprise a combination of green-lipped mussel powder and eggshell membrane powder. In other embodiments, the dietary supplement may comprise vitamin D3, vitamin C, and Ginger roots extract.

The present invention provides an edible blended vegetable oil for reducing blood lipids and cholesterol. The trace elements in the edible blended vegetable oil include 15-300 mg/kg of polyphenols, 290-1700 mg/kg of β-sitosterol, 260-1500 mg/kg of campesterol, 150-1000 mg/kg of stigmasterol, 140-600 mg/kg of squalene, 50-160 mg/kg of parkerol, 40-120 mg/kg of γ-tocotrienol. The prepared edible blended vegetable oil of the present invention can achieve the effect of reducing blood lipids and cholesterol through a synergistic effect within the trace elements and a reasonable ratio within fatty acids. It is suitable for people with different health needs and has a broad market prospect and application value.

The present invention provides an edible blended vegetable oil for reducing blood lipids and cholesterol. The trace elements in the edible blended vegetable oil include 15-300 mg/kg of polyphenols, 290-1700 mg/kg of β-sitosterol, 260-1500 mg/kg of campesterol, 150-1000 mg/kg of stigmasterol, 140-600 mg/kg of squalene, 50-160 mg/kg of parkerol, 40-120 mg/kg of γ-tocotrienol. The prepared edible blended vegetable oil of the present invention can achieve the effect of reducing blood lipids and cholesterol through a synergistic effect within the trace elements and a reasonable ratio within fatty acids. It is suitable for people with different health needs and has a broad market prospect and application value.

The present invention provides an edible blended vegetable oil for reducing blood lipids and cholesterol. The trace elements in the edible blended vegetable oil include 15-300 mg/kg of polyphenols, 290-1700 mg/kg of β-sitosterol, 260-1500 mg/kg of campesterol, 150-1000 mg/kg of stigmasterol, 140-600 mg/kg of squalene, 50-160 mg/kg of parkerol, 40-120 mg/kg of γ-tocotrienol. The prepared edible blended vegetable oil of the present invention can achieve the effect of reducing blood lipids and cholesterol through a synergistic effect within the trace elements and a reasonable ratio within fatty acids. It is suitable for people with different health needs and has a broad market prospect and application value.